ProfileGDS5678 / 1441778_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 47% 47% 46% 47% 49% 47% 47% 47% 46% 47% 46% 48% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1781248
GSM967853U87-EV human glioblastoma xenograft - Control 23.1175147
GSM967854U87-EV human glioblastoma xenograft - Control 33.1141347
GSM967855U87-EV human glioblastoma xenograft - Control 43.0153746
GSM967856U87-EV human glioblastoma xenograft - Control 53.0551347
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2601949
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1736147
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1035247
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0736547
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0756346
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.111247
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0461446
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1320748
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1157747